Clinical trial
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic…
NCT00108823 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00108823 |
|---|---|
| Title | The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121) |
| Official title | A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease, COPD |
| Intervention type | Drug |
| Interventions | Roflumilast |
| Enrollment | 550 |
| Start date | Oct 1, 2004 |
| First posted | Apr 20, 2005 |
| Last update posted | Oct 26, 2016 |
| Countries | Canada, France, Poland, South Africa, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: